Bullfrog AI (BFRG) Competitors

Acumen Pharmaceuticals (NASDAQ:ABOS) and Bullfrog AI (NASDAQ:BFRG) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, community ranking, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

Does the media prefer ABOS or BFRG?

In the previous week, Bullfrog AI had 1 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 2 mentions for Bullfrog AI and 1 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 1.54 beat Bullfrog AI's score of -0.37 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acumen Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Bullfrog AI	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has higher earnings & valuation, ABOS or BFRG?

Bullfrog AI has higher revenue and earnings than Acumen Pharmaceuticals. Bullfrog AI is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$52.37M	-$1.71	-0.60
Bullfrog AI	$60K	276.17	-$5.36M	-$0.86	-2.05

Do institutionals & insiders believe in ABOS or BFRG?

71.0% of Acumen Pharmaceuticals shares are held by institutional investors. Comparatively, 1.0% of Bullfrog AI shares are held by institutional investors. 7.1% of Acumen Pharmaceuticals shares are held by insiders. Comparatively, 33.9% of Bullfrog AI shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Does the MarketBeat Community favor ABOS or BFRG?

Acumen Pharmaceuticals received 27 more outperform votes than Bullfrog AI when rated by MarketBeat users.

Company	Underperform	Outperform
Acumen Pharmaceuticals	Outperform Votes 27 72.97%	Underperform Votes 10 27.03%
Bullfrog AI	N/A	N/A

Do analysts rate ABOS or BFRG?

Acumen Pharmaceuticals currently has a consensus price target of $7.33, indicating a potential upside of 618.95%. Given Acumen Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Acumen Pharmaceuticals is more favorable than Bullfrog AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33
Bullfrog AI	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Is ABOS or BFRG more profitable?

Acumen Pharmaceuticals' return on equity of -32.99% beat Bullfrog AI's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-32.99%	-27.99%
Bullfrog AI	N/A	-141.39%	-124.63%

Which has more volatility and risk, ABOS or BFRG?

Acumen Pharmaceuticals has a beta of 0.1, meaning that its share price is 90% less volatile than the S&P 500. Comparatively, Bullfrog AI has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.

Summary

Acumen Pharmaceuticals beats Bullfrog AI on 10 of the 16 factors compared between the two stocks.